{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T21:53:05Z","timestamp":1787176385772,"version":"build-2736575974"},"reference-count":110,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":1746,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["li.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Laboratory Investigation"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1038\/s41374-017-0003-6","type":"journal-article","created":{"date-parts":[[2018,1,16]],"date-time":"2018-01-16T17:39:12Z","timestamp":1516124352000},"page":"414-426","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms"],"prefix":"10.1016","volume":"98","author":[{"given":"Inga-Marie","family":"Schaefer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6475-8345","authenticated-orcid":false,"given":"Jason L.","family":"Hornick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1155-0481","authenticated-orcid":false,"given":"Judith V.M.G.","family":"Bov\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/s41374-017-0003-6_bib1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1038\/s41374-017-0003-6_bib2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"10.1038\/s41374-017-0003-6_bib3","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1101\/gad.189365.112","article-title":"Links between metabolism and cancer","volume":"26","author":"Dang","year":"2012","journal-title":"Genes Dev"},{"key":"10.1038\/s41374-017-0003-6_bib4","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1101\/gad.217406.113","article-title":"What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer","volume":"27","author":"Losman","year":"2013","journal-title":"Genes Dev"},{"key":"10.1038\/s41374-017-0003-6_bib5","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/ng.1004","article-title":"Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome","volume":"43","author":"Pansuriya","year":"2011","journal-title":"Nat Genet"},{"key":"10.1038\/s41374-017-0003-6_bib6","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/ng.994","article-title":"Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2","volume":"43","author":"Amary","year":"2011","journal-title":"Nat Genet"},{"key":"10.1038\/s41374-017-0003-6_bib7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrc1013","article-title":"A role for mitochondrial enzymes in inherited neoplasia and beyond","volume":"3","author":"Eng","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/s41374-017-0003-6_bib8","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1073\/pnas.1009199108","article-title":"Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations","volume":"108","author":"Janeway","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/s41374-017-0003-6_bib9","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ng849","article-title":"Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer","volume":"30","author":"Tomlinson","year":"2002","journal-title":"Nat Genet"},{"key":"10.1038\/s41374-017-0003-6_bib10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1042\/bj0310645","article-title":"Metabolism of ketonic acids in animal tissues","volume":"31","author":"Krebs","year":"1937","journal-title":"Biochem J"},{"key":"10.1038\/s41374-017-0003-6_bib11","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s12013-013-9750-1","article-title":"Citric acid cycle and role of its intermediates in metabolism","volume":"68","author":"Akram","year":"2014","journal-title":"Cell Biochem Biophys"},{"key":"10.1038\/s41374-017-0003-6_bib12","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1042\/BST20160099","article-title":"Isocitrate dehydrogenase (IDH), succinate dehydrogenase (SDH), fumarate hydratase (FH): three players for one phenotype in cancer?","volume":"44","author":"Laurenti","year":"2016","journal-title":"Biochem Soc Trans"},{"issue":"Suppl","key":"10.1038\/s41374-017-0003-6_bib13","first-page":"K45","article-title":"Isocitrate dehydrogenase and related oxidative decarboxylases","volume":"117","author":"Dalziel","year":"1980","journal-title":"FEBS Lett"},{"key":"10.1038\/s41374-017-0003-6_bib14","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"key":"10.1038\/s41374-017-0003-6_bib15","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1200\/JCO.2010.28.3762","article-title":"IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication","volume":"28","author":"Paschka","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41374-017-0003-6_bib16","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/leu.2016.275","article-title":"Isocitrate dehydrogenase mutations in myeloid malignancies","volume":"31","author":"Medeiros","year":"2017","journal-title":"Leukemia"},{"key":"10.1038\/s41374-017-0003-6_bib17","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/modpathol.2016.239","article-title":"Recurrent IDH2 R172X mutations in sinonasal undifferentiated carcinoma","volume":"30","author":"Jo","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1038\/s41374-017-0003-6_bib18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1634\/theoncologist.2011-0386","article-title":"Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping","volume":"17","author":"Borger","year":"2012","journal-title":"Oncologist"},{"key":"10.1038\/s41374-017-0003-6_bib19","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/path.2913","article-title":"IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours","volume":"224","author":"Amary","year":"2011","journal-title":"J Pathol"},{"key":"10.1038\/s41374-017-0003-6_bib20","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.ajpath.2013.01.012","article-title":"R132C IDH1 mutations are found in spindle cell hemangiomas and not in other vascular tumors or malformations","volume":"182","author":"Kurek","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1038\/s41374-017-0003-6_bib21","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1200\/JCO.2009.21.9832","article-title":"Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas","volume":"27","author":"Sanson","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41374-017-0003-6_bib22","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1158\/1078-0432.CCR-09-0715","article-title":"IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas","volume":"15","author":"Nobusawa","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1038\/s41374-017-0003-6_bib23","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00401-009-0561-9","article-title":"Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas","volume":"118","author":"Hartmann","year":"2009","journal-title":"Acta Neuropathol"},{"key":"10.1038\/s41374-017-0003-6_bib24","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1634\/theoncologist.2015-0210","article-title":"Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma","volume":"20","author":"Goyal","year":"2015","journal-title":"Oncologist"},{"key":"10.1038\/s41374-017-0003-6_bib25","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.24072","article-title":"Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML","volume":"90","author":"DiNardo","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1038\/s41374-017-0003-6_bib26","doi-asserted-by":"crossref","DOI":"10.1186\/s13569-017-0074-6","article-title":"IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas","volume":"7","author":"Cleven","year":"2017","journal-title":"Clin Sarcoma Res"},{"key":"10.1038\/s41374-017-0003-6_bib27","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.bbrc.2015.09.070","article-title":"A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas","volume":"466","author":"Fujii","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1038\/s41374-017-0003-6_bib28","unstructured":"Fletcher CDM. WHO classification of tumours of soft tissue and bone. IARC Press, Lyon, 2013."},{"key":"10.1038\/s41374-017-0003-6_bib29","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1111\/j.1582-4934.2008.00406.x","article-title":"Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro","volume":"13","author":"Schrage","year":"2009","journal-title":"J Cell Mol Med"},{"key":"10.1038\/s41374-017-0003-6_bib30","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/ng.2668","article-title":"Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma","volume":"45","author":"Tarpey","year":"2013","journal-title":"Nat Genet"},{"key":"10.1038\/s41374-017-0003-6_bib31","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1101\/gr.160598.113","article-title":"Unique mutation portraits and frequent COL2A1 gene alteration in chondrosarcoma","volume":"24","author":"Totoki","year":"2014","journal-title":"Genome Res"},{"key":"10.1038\/s41374-017-0003-6_bib32","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1158\/1078-0432.CCR-12-3647","article-title":"Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy","volume":"19","author":"Zhang","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1038\/s41374-017-0003-6_bib33","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nrc2869","article-title":"Cartilage tumours and bone development: molecular pathology and possible therapeutic targets","volume":"10","author":"Bovee","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/s41374-017-0003-6_bib34","first-page":"557","article-title":"Enchondromatosis: insights on the different subtypes","volume":"3","author":"Pansuriya","year":"2010","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1038\/s41374-017-0003-6_bib35","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1634\/theoncologist.2011-0200","article-title":"Incidence, predictive factors, and prognosis of chondrosarcoma in patients with Ollier disease and Maffucci syndrome: an international multicenter study of 161 patients","volume":"16","author":"Verdegaal","year":"2011","journal-title":"Oncologist"},{"key":"10.1038\/s41374-017-0003-6_bib36","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1038\/s41374-017-0003-6_bib37","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1084\/jem.20092506","article-title":"Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations","volume":"207","author":"Gross","year":"2010","journal-title":"J Exp Med"},{"key":"10.1038\/s41374-017-0003-6_bib38","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/nature09132","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"465","author":"Dang","year":"2010","journal-title":"Nature"},{"key":"10.1038\/s41374-017-0003-6_bib39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1038\/s41374-017-0003-6_bib40","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1038\/s41374-017-0003-6_bib41","doi-asserted-by":"crossref","first-page":"14832","DOI":"10.18632\/oncotarget.4024","article-title":"The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo","volume":"6","author":"Suijker","year":"2015","journal-title":"Oncotarget"},{"key":"10.1038\/s41374-017-0003-6_bib42","doi-asserted-by":"crossref","first-page":"e0131998","DOI":"10.1371\/journal.pone.0131998","article-title":"Mutant IDH1 dysregulates the differentiation of mesenchymal stem cells in association with gene-specific histone modifications to cartilage- and bone-related henes","volume":"10","author":"Jin","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1038\/s41374-017-0003-6_bib43","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1158\/0008-5472.CAN-12-2852","article-title":"Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas","volume":"73","author":"Jin","year":"2013","journal-title":"Cancer Res"},{"key":"10.1038\/s41374-017-0003-6_bib44","doi-asserted-by":"crossref","first-page":"12505","DOI":"10.18632\/oncotarget.3723","article-title":"Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines","volume":"6","author":"Suijker","year":"2015","journal-title":"Oncotarget"},{"key":"10.1038\/s41374-017-0003-6_bib45","doi-asserted-by":"crossref","first-page":"e0133813","DOI":"10.1371\/journal.pone.0133813","article-title":"Treatment with a small molecule mutant IDH1 inhibitor suppresses tumorigenic activity and decreases production of the oncometabolite 2-hydroxyglutarate in human chondrosarcoma cells","volume":"10","author":"Li","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1038\/s41374-017-0003-6_bib46","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/his.12666","article-title":"Periosteal chondrosarcoma: a histopathological and molecular analysis of a rare chondrosarcoma subtype","volume":"67","author":"Cleven","year":"2015","journal-title":"Histopathology"},{"key":"10.1038\/s41374-017-0003-6_bib47","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2559.2011.04010.x","article-title":"IDH1 mutations are not found in cartilaginous tumours other than central and periosteal chondrosarcomas and enchondromas","volume":"60","author":"Damato","year":"2012","journal-title":"Histopathology"},{"key":"10.1038\/s41374-017-0003-6_bib48","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10014-012-0085-1","article-title":"Frequent IDH1\/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma","volume":"29","author":"Arai","year":"2012","journal-title":"Brain Tumor Pathol"},{"key":"10.1038\/s41374-017-0003-6_bib49","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.ejhg.5201904","article-title":"Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD","volume":"16","author":"Pasini","year":"2008","journal-title":"Eur J Hum Genet"},{"key":"10.1038\/s41374-017-0003-6_bib50","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2796.2009.02110.x","article-title":"The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications","volume":"266","author":"Stratakis","year":"2009","journal-title":"J Intern Med"},{"key":"10.1038\/s41374-017-0003-6_bib51","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1210\/jc.2007-0797","article-title":"Genetics of carney triad: recurrent losses at chromosome 1 but lack of germline mutations in genes associated with paragangliomas and gastrointestinal stromal tumors","volume":"92","author":"Matyakhina","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1038\/s41374-017-0003-6_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/path.1700360102","article-title":"Familial and bilateral tumours of the carotid body","volume":"36","author":"Chase","year":"1933","journal-title":"J Pathol Bacteriol"},{"key":"10.1038\/s41374-017-0003-6_bib53","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1055\/s-0031-1301302","article-title":"An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes","volume":"44","author":"Gimenez-Roqueplo","year":"2012","journal-title":"Horm Metab Res"},{"key":"10.1038\/s41374-017-0003-6_bib54","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1056\/NEJMoa020152","article-title":"Germ-line mutations in nonsyndromic pheochromocytoma","volume":"346","author":"Neumann","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1038\/s41374-017-0003-6_bib55","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2796.2009.02111.x","article-title":"SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes","volume":"266","author":"Pasini","year":"2009","journal-title":"J Intern Med"},{"key":"10.1038\/s41374-017-0003-6_bib56","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1093\/hmg\/ddq206","article-title":"SDHA is a tumor suppressor gene causing paraganglioma","volume":"19","author":"Burnichon","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1038\/s41374-017-0003-6_bib57","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/ng.533","article-title":"Germline mutations in TMEM127 confer susceptibility to pheochromocytoma","volume":"42","author":"Qin","year":"2010","journal-title":"Nat Genet"},{"key":"10.1038\/s41374-017-0003-6_bib58","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ng.861","article-title":"Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma","volume":"43","author":"Comino-Mendez","year":"2011","journal-title":"Nat Genet"},{"key":"10.1038\/s41374-017-0003-6_bib59","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1038\/s41374-017-0003-6_bib60","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1086\/321282","article-title":"Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma","volume":"69","author":"Astuti","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1038\/s41374-017-0003-6_bib61","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/81551","article-title":"Mutations in SDHC cause autosomal dominant paraganglioma, type 3","volume":"26","author":"Niemann","year":"2000","journal-title":"Nat Genet"},{"key":"10.1038\/s41374-017-0003-6_bib62","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1126\/science.287.5454.848","article-title":"Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma","volume":"287","author":"Baysal","year":"2000","journal-title":"Science"},{"key":"10.1038\/s41374-017-0003-6_bib63","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1126\/science.1175689","article-title":"SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma","volume":"325","author":"Hao","year":"2009","journal-title":"Science"},{"key":"10.1038\/s41374-017-0003-6_bib64","doi-asserted-by":"crossref","first-page":"T91","DOI":"10.1530\/ERC-15-0268","article-title":"15 years of paraganglioma: clinical manifestations of paraganglioma syndromes types 1-5","volume":"22","author":"Benn","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"10.1038\/s41374-017-0003-6_bib65","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1093\/hmg\/ddt639","article-title":"Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas","volume":"23","author":"Castro-Vega","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1038\/s41374-017-0003-6_bib66","doi-asserted-by":"crossref","first-page":"E2046","DOI":"10.1210\/jc.2014-1659","article-title":"Germline FH mutations presenting with pheochromocytoma","volume":"99","author":"Clark","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1038\/s41374-017-0003-6_bib67","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ccr.2013.04.018","article-title":"SDH mutations establish a hypermethylator phenotype in paraganglioma","volume":"23","author":"Letouze","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1038\/s41374-017-0003-6_bib68","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrurol.2010.47","article-title":"The genetic basis of kidney cancer: a metabolic disease","volume":"7","author":"Linehan","year":"2010","journal-title":"Nat Rev Urol"},{"key":"10.1038\/s41374-017-0003-6_bib69","doi-asserted-by":"crossref","unstructured":"Gupta S, Zhang J, Milosevic D, et al. Primary renal paragangliomas and renal neoplasia associated with pheochromocytoma\/paraganglioma: analysis of von Hippel-Lindau (VHL), succinate dehydrogenase (SDHX) and transmembrane protein 127 (TMEM127). Endocr Pathol. 2017;28:253\u2013268.","DOI":"10.1007\/s12022-017-9489-0"},{"key":"10.1038\/s41374-017-0003-6_bib70","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1586\/era.13.57","article-title":"Aerobic glycolysis: a novel target in kidney cancer","volume":"13","author":"Shuch","year":"2013","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1038\/s41374-017-0003-6_bib71","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/j.juro.2012.08.030","article-title":"Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer","volume":"188","author":"Ricketts","year":"2012","journal-title":"J Urol"},{"key":"10.1038\/s41374-017-0003-6_bib72","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/modpathol.2014.86","article-title":"Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma","volume":"28","author":"Williamson","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1038\/s41374-017-0003-6_bib73","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/his.13183","article-title":"A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma","volume":"71","author":"Smith","year":"2017","journal-title":"Histopathology"},{"key":"10.1038\/s41374-017-0003-6_bib74","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/PAS.0b013e3182671178","article-title":"Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation","volume":"37","author":"Miettinen","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/s41374-017-0003-6_bib75","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/modpathol.2012.153","article-title":"Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors","volume":"26","author":"Wagner","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1038\/s41374-017-0003-6_bib76","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/modpathol.2012.186","article-title":"SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors","volume":"26","author":"Oudijk","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1038\/s41374-017-0003-6_bib77","doi-asserted-by":"crossref","first-page":"C33","DOI":"10.1530\/ERC-12-0118","article-title":"Succinate dehydrogenase (SDHx) mutations in pituitary tumors: could this be a new role for mitochondrial complex II and\/or Krebs cycle defects?","volume":"19","author":"Xekouki","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"10.1038\/s41374-017-0003-6_bib78","first-page":"12188","article-title":"A novel germline mutation in SDHA identified in a rare case of gastrointestinal stromal tumor complicated with renal cell carcinoma","volume":"8","author":"Jiang","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1038\/s41374-017-0003-6_bib79","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/j.1365-2559.2012.04300.x","article-title":"Loss of succinate dehydrogenase subunit B (SDHB) expression is limited to a distinctive subset of gastric wild-type gastrointestinal stromal tumours: a comprehensive genotype-phenotype correlation study","volume":"61","author":"Doyle","year":"2012","journal-title":"Histopathology"},{"key":"10.1038\/s41374-017-0003-6_bib80","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1530\/ERC-14-0254","article-title":"Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad","volume":"21","author":"Haller","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1038\/s41374-017-0003-6_bib81","doi-asserted-by":"crossref","first-page":"268ra177","DOI":"10.1126\/scitranslmed.3009961","article-title":"Recurrent epimutation of SDHC in gastrointestinal stromal tumors","volume":"6","author":"Killian","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1038\/s41374-017-0003-6_bib82","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/ejhg.2015.142","article-title":"Carney triad can be (rarely) associated with germline succinate dehydrogenase defects","volume":"24","author":"Boikos","year":"2016","journal-title":"Eur J Hum Genet"},{"key":"10.1038\/s41374-017-0003-6_bib83","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1097\/PAS.0000000000000685","article-title":"Conventional risk stratification fails to predict progression of succinate dehydrogenase-deficient gastrointestinal stromal tumors: a clinicopathologic study of 76 cases","volume":"40","author":"Mason","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/s41374-017-0003-6_bib84","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1093\/hmg\/ddm275","article-title":"Succinate inhibition of alpha-ketoglutarate-dependent enzymes in a yeast model of paraganglioma","volume":"16","author":"Smith","year":"2007","journal-title":"Hum Mol Genet"},{"key":"10.1038\/s41374-017-0003-6_bib85","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1101\/gad.191056.112","article-title":"Inhibition of alpha-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors","volume":"26","author":"Xiao","year":"2012","journal-title":"Genes Dev"},{"key":"10.1038\/s41374-017-0003-6_bib86","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-8-89","article-title":"Inhibition of succinate dehydrogenase dysregulates histone modification in mammalian cells","volume":"8","author":"Cervera","year":"2009","journal-title":"Mol Cancer"},{"key":"10.1038\/s41374-017-0003-6_bib87","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/jamaoncol.2016.0256","article-title":"Molecular subtypes of KIT\/PDGFRA wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health Gastrointestinal Stromal Tumor Clinic","volume":"2","author":"Boikos","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1038\/s41374-017-0003-6_bib88","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/modpathol.2013.86","article-title":"Succinate dehydrogenase deficiency is associated with decreased 5-hydroxymethylcytosine production in gastrointestinal stromal tumors: implications for mechanisms of tumorigenesis","volume":"26","author":"Mason","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1038\/s41374-017-0003-6_bib89","doi-asserted-by":"crossref","first-page":"38777","DOI":"10.18632\/oncotarget.6091","article-title":"Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma\/pheochromocytoma and smooth muscle tumors","volume":"6","author":"Hoekstra","year":"2015","journal-title":"Oncotarget"},{"key":"10.1038\/s41374-017-0003-6_bib90","unstructured":"Pithukpakorn M, Toro JR. Hereditary leiomyomatosis and renal cell cancer. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. Gene Reviews(R). Seattle, WA, University of Washington, 1993."},{"key":"10.1038\/s41374-017-0003-6_bib91","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1097\/PAS.0000000000000703","article-title":"Fumarase-deficient uterine Leiomyomas: an immunohistochemical, molecular genetic, and clinicopathologic study of 86 cases","volume":"40","author":"Miettinen","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/s41374-017-0003-6_bib92","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1097\/PAS.0000000000000520","article-title":"Morphology and immunohistochemistry for 2SC and FH aid in detection of fumarate hydratase gene aberrations in uterine Leiomyomas from young patients","volume":"39","author":"Joseph","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/s41374-017-0003-6_bib93","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/modpathol.2013.215","article-title":"Uterine smooth muscle tumors with features suggesting fumarate hydratase aberration: detailed morphologic analysis and correlation with S-(2-succino)-cysteine immunohistochemistry","volume":"27","author":"Reyes","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1038\/s41374-017-0003-6_bib94","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/path.2932","article-title":"Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status","volume":"225","author":"Bardella","year":"2011","journal-title":"J Pathol"},{"key":"10.1038\/s41374-017-0003-6_bib95","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.celrep.2013.02.013","article-title":"Inhibition of mitochondrial aconitase by succination in fumarate hydratase deficiency","volume":"3","author":"Ternette","year":"2013","journal-title":"Cell Rep"},{"key":"10.1038\/s41374-017-0003-6_bib96","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/DAD.0000000000000580","article-title":"Loss of fumarate hydratase and aberrant protein succination detected with S-(2-succino)-cysteine staining to identify patients with multiple cutaneous and uterine Leiomyomatosis and hereditary Leiomyomatosis and renal cell cancer syndrome","volume":"38","author":"Llamas-Velasco","year":"2016","journal-title":"Am J Dermatopathol"},{"key":"10.1038\/s41374-017-0003-6_bib97","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1158\/2159-8290.CD-13-0092","article-title":"Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor","volume":"3","author":"Killian","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1038\/s41374-017-0003-6_bib98","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.biochi.2017.01.004","article-title":"Exposure to high levels of fumarate and succinate leads to apoptotic cytotoxicity and altered global DNA methylation profiles in vitro","volume":"135","author":"Wentzel","year":"2017","journal-title":"Biochimie"},{"key":"10.1038\/s41374-017-0003-6_bib99","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012","journal-title":"Nature"},{"key":"10.1038\/s41374-017-0003-6_bib100","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.sbi.2010.08.006","article-title":"Structural studies on human 2-oxoglutarate dependent oxygenases","volume":"20","author":"McDonough","year":"2010","journal-title":"Curr Opin Struct Biol"},{"key":"10.1038\/s41374-017-0003-6_bib101","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/embor.2011.43","article-title":"The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases","volume":"12","author":"Chowdhury","year":"2011","journal-title":"EMBO Rep"},{"key":"10.1038\/s41374-017-0003-6_bib102","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ccr.2005.06.017","article-title":"HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability","volume":"8","author":"Isaacs","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1038\/s41374-017-0003-6_bib103","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2004.11.022","article-title":"Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase","volume":"7","author":"Selak","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1038\/s41374-017-0003-6_bib104","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1021\/ml300225h","article-title":"Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo","volume":"3","author":"Popovici-Muller","year":"2012","journal-title":"ACS Med Chem Lett"},{"key":"10.1038\/s41374-017-0003-6_bib105","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1126\/science.1236062","article-title":"An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells","volume":"340","author":"Rohle","year":"2013","journal-title":"Science"},{"key":"10.1038\/s41374-017-0003-6_bib106","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1126\/science.1234769","article-title":"Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation","volume":"340","author":"Wang","year":"2013","journal-title":"Science"},{"key":"10.1038\/s41374-017-0003-6_bib107","doi-asserted-by":"crossref","unstructured":"Kim ES. Enasidenib: first global approval. Drugs. 2017;77:1705\u20131711.","DOI":"10.1007\/s40265-017-0813-2"},{"key":"10.1038\/s41374-017-0003-6_bib108","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1097\/PAS.0b013e3182260752","article-title":"Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age","volume":"35","author":"Miettinen","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/s41374-017-0003-6_bib109","doi-asserted-by":"crossref","first-page":"e56827","DOI":"10.1371\/journal.pone.0056827","article-title":"High-throughput screening for growth inhibitors using a yeast model of familial paraganglioma","volume":"8","author":"Bancos","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1038\/s41374-017-0003-6_bib110","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1158\/1078-0432.CCR-13-0304","article-title":"Molecular pathways: fumarate hydratase-deficient kidney cancer--targeting the Warburg effect in cancer","volume":"19","author":"Linehan","year":"2013","journal-title":"Clin Cancer Res"}],"container-title":["Laboratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41374-017-0003-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41374-017-0003-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683722011230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683722011230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41374-017-0003-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T19:34:48Z","timestamp":1758396888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0023683722011230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":110,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0023683722011230"],"URL":"https:\/\/doi.org\/10.1038\/s41374-017-0003-6","relation":{},"ISSN":["0023-6837"],"issn-type":[{"value":"0023-6837","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms","name":"articletitle","label":"Article Title"},{"value":"Laboratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41374-017-0003-6","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}